Cargando…
Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression
Introduction: Osteosarcoma (OS), the primary malignant bone tumor, has a low survival rate for recurrent patients. Latest reports indicated that cancer-associated fibroblasts (CAFs) were the main component of tumor microenvironment, and would generate a variable role in the progression of tumors. Ho...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333483/ https://www.ncbi.nlm.nih.gov/pubmed/37441535 http://dx.doi.org/10.3389/fphar.2023.1136960 |
_version_ | 1785070665415524352 |
---|---|
author | Zhihao, Zhang Cheng, Ju Xiaoshuang, Zuo Yangguang, Ma Tingyu, Wu Yongyong, Yang Zhou, Yao Jie, Zhou Tao, Zhang Xueyu, Hu Zhe, Wang |
author_facet | Zhihao, Zhang Cheng, Ju Xiaoshuang, Zuo Yangguang, Ma Tingyu, Wu Yongyong, Yang Zhou, Yao Jie, Zhou Tao, Zhang Xueyu, Hu Zhe, Wang |
author_sort | Zhihao, Zhang |
collection | PubMed |
description | Introduction: Osteosarcoma (OS), the primary malignant bone tumor, has a low survival rate for recurrent patients. Latest reports indicated that cancer-associated fibroblasts (CAFs) were the main component of tumor microenvironment, and would generate a variable role in the progression of tumors. However, the role of CAFs is still few known in osteosarcoma. Methods: The processed RNA-seq data and the corresponding clinical and molecular information were retrieved from the Cancer Genome Atlas Program (TCGA) database and processed data of tumor tissue was obtained from Gene Expression Omnibus (GEO) database. Xcell method was used in data processing, and Gene set variation analysis (GSVA) was used to calculates enrichment scores. Nomogram was constructed to evaluate prognostic power of the predictive model. And the construction of risk scores and assessment of prognostic predictive were based on the LASSO model. Results: This study classified Cancer Genome Atlas (TCGA) cohort into high and low CAFs infiltrate phenotype with different CAFs infiltration enrichment scores. Then TOP 9 genes were screened as prognostic signatures among 2,488 differentially expressed genes between the two groups. Key prognostic molecules were CGREF1, CORT and RHBDL2 and the risk score formula is: Risk-score = CGREF1*0.004 + CORT*0.004 + RHBDL2*0.002. The signatures were validated to be independent prognostic factors to predict tumor prognosis with single-factor COX and multi-factor COX regression analyses and Norton chart. The risk score expression of risk score model genes could predict the drug resistance, and significant differences could be found between the high and low scoring groups for 17-AAG, AZD6244, PD-0325901 and Sorafenib. Discussion: To sum up, this article validated the prediction role of CAF infiltration in the prognosis of OS, which might shed light on the treatment of OS. |
format | Online Article Text |
id | pubmed-10333483 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103334832023-07-12 Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression Zhihao, Zhang Cheng, Ju Xiaoshuang, Zuo Yangguang, Ma Tingyu, Wu Yongyong, Yang Zhou, Yao Jie, Zhou Tao, Zhang Xueyu, Hu Zhe, Wang Front Pharmacol Pharmacology Introduction: Osteosarcoma (OS), the primary malignant bone tumor, has a low survival rate for recurrent patients. Latest reports indicated that cancer-associated fibroblasts (CAFs) were the main component of tumor microenvironment, and would generate a variable role in the progression of tumors. However, the role of CAFs is still few known in osteosarcoma. Methods: The processed RNA-seq data and the corresponding clinical and molecular information were retrieved from the Cancer Genome Atlas Program (TCGA) database and processed data of tumor tissue was obtained from Gene Expression Omnibus (GEO) database. Xcell method was used in data processing, and Gene set variation analysis (GSVA) was used to calculates enrichment scores. Nomogram was constructed to evaluate prognostic power of the predictive model. And the construction of risk scores and assessment of prognostic predictive were based on the LASSO model. Results: This study classified Cancer Genome Atlas (TCGA) cohort into high and low CAFs infiltrate phenotype with different CAFs infiltration enrichment scores. Then TOP 9 genes were screened as prognostic signatures among 2,488 differentially expressed genes between the two groups. Key prognostic molecules were CGREF1, CORT and RHBDL2 and the risk score formula is: Risk-score = CGREF1*0.004 + CORT*0.004 + RHBDL2*0.002. The signatures were validated to be independent prognostic factors to predict tumor prognosis with single-factor COX and multi-factor COX regression analyses and Norton chart. The risk score expression of risk score model genes could predict the drug resistance, and significant differences could be found between the high and low scoring groups for 17-AAG, AZD6244, PD-0325901 and Sorafenib. Discussion: To sum up, this article validated the prediction role of CAF infiltration in the prognosis of OS, which might shed light on the treatment of OS. Frontiers Media S.A. 2023-06-27 /pmc/articles/PMC10333483/ /pubmed/37441535 http://dx.doi.org/10.3389/fphar.2023.1136960 Text en Copyright © 2023 Zhihao, Cheng, Xiaoshuang, Yangguang, Tingyu, Yongyong, Zhou, Jie, Tao, Xueyu and Zhe. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhihao, Zhang Cheng, Ju Xiaoshuang, Zuo Yangguang, Ma Tingyu, Wu Yongyong, Yang Zhou, Yao Jie, Zhou Tao, Zhang Xueyu, Hu Zhe, Wang Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression |
title | Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression |
title_full | Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression |
title_fullStr | Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression |
title_full_unstemmed | Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression |
title_short | Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression |
title_sort | cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333483/ https://www.ncbi.nlm.nih.gov/pubmed/37441535 http://dx.doi.org/10.3389/fphar.2023.1136960 |
work_keys_str_mv | AT zhihaozhang cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression AT chengju cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression AT xiaoshuangzuo cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression AT yangguangma cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression AT tingyuwu cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression AT yongyongyang cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression AT zhouyao cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression AT jiezhou cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression AT taozhang cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression AT xueyuhu cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression AT zhewang cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression |